

Exhibit 42

IN THE UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
MDL NO. 16-2738 (MAS)(RLS)

IN RE: JOHNSON & JOHNSON :
TALCUM POWDER PRODUCTS :
MARKETING, SALES PRACTICES :
AND PRODUCTS LIABILITY :
LITIGATION :

Remote deposition of ANNE MCTIERNAN,
M.D., Ph.D., taken in the above-entitled matter
before Suzanne J. Stotz, Registered
Professional Reporter, Certified Realtime
Reporter, Certified Court Reporter, and
Notary Public within the State of Washington,
taken on Tuesday, April 2, 2024, commencing at
8:58 a.m. PDT.

<p style="text-align: right;">Page 2</p> <p>1 APPEARANCES:</p> <p>2</p> <p>3 ATTORNEYS FOR PLAINTIFF:</p> <p>4 (Via videoconference)</p> <p>5 ASHCRAFT & GEREL, LLP</p> <p>6 BY: MICHELLE A. PARFITT, ESQ., and</p> <p>7 BY: PATRICK K. LYONS, ESQ.</p> <p>8 4900 Seminary Road, Suite 650</p> <p>9 Alexandria, Virginia 22311</p> <p>10 (844) 680-0339</p> <p>11 mparfitt@ashcraftlaw.com</p> <p>12 plyons@ashcraftlaw.com</p> <p>13 - and -</p> <p>14 (Via videoconference)</p> <p>15 LEVIN PAPANTONIO RAFFERTY, P.A.</p> <p>16 BY: CHRISTOPHER V. TISI, ESQ.</p> <p>17 316 South Baylen Street</p> <p>18 Pensacola, Florida 32502</p> <p>19 (850) 435-7000</p> <p>20 ctisi@levinlaw.com</p> <p>21</p> <p>22 ATTORNEYS FOR THE DEFENDANT:</p> <p>23 (Via videoconference)</p> <p>24 SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP</p> <p>25 BY: CATHERINE I. MULLALEY, ESQ.</p> <p>500 Boylan Street</p> <p>Boston, Massachusetts 02116</p> <p>(617) 573-4800</p> <p>kate.mullaley@skadden.com</p> <p>- and -</p> <p>(Via videoconference)</p> <p>SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP</p> <p>BY: RACHEL PAPALSKI, ESQ.</p> <p>One Manhattan West</p> <p>New York, New York 10001</p> <p>(212) 735-3000</p> <p>rachel.papalski@skadden.com</p>	<p style="text-align: right;">Page 4</p> <p>1 INDEX (Continued)</p> <p>2</p> <p>3 EXHIBITS (Continued)</p> <p>4 Exhibit</p> <p>5 Name Description Page No.</p> <p>6 Defendant's Second Amended Expert Report 78</p> <p>7 Exhibit D5 Report of Anne</p> <p>8 McTiernan, MD, Ph.D.,</p> <p>9 dated November 15, 2023</p> <p>10 Defendant's Amended Expert Report 79</p> <p>11 Exhibit D6 of Anne McTiernan, MD,</p> <p>12 Ph.D., dated June 24,</p> <p>13 2021</p> <p>14</p> <p>15 Defendant's Redline between the 80</p> <p>16 Exhibit D7 Amended Expert Report</p> <p>17 of Anne McTiernan, MD,</p> <p>18 Ph.D., dated June 24,</p> <p>19 2021, and the Second</p> <p>20 Amended Expert Report</p> <p>21 of Anne McTiernan, MD,</p> <p>22 Ph.D., dated</p> <p>23 November 15, 2023</p> <p>24</p> <p>25 Defendant's Rule 26 Expert Report 81</p> <p>16 Exhibit D8 of Anne McTiernan, MD,</p> <p>17 Ph.D., dated</p> <p>18 November 16, 2018</p> <p>19 Defendant's Article entitled, 109</p> <p>20 Exhibit D9 "Effects of risk</p> <p>21 factors for ovarian</p> <p>22 cancer in women with</p> <p>23 and without</p> <p>24 endometriosis," by Minh</p> <p>25 Tung Phung, M.P.H.,</p> <p>Ph.D., et al.</p>
<p style="text-align: right;">Page 3</p> <p>1 INDEX</p> <p>2</p> <p>3 EXAMINATION</p> <p>4 Page No.</p> <p>5 ANNE MCTIERNAN, M.D., PH.D.</p> <p>6 BY MS. MULLALEY 10</p> <p>7 BY MS. PARFITT 190</p> <p>8 BY MS. MULLALEY 197</p> <p>9 BY MS. PARFITT 199</p> <p>10</p> <p>11</p> <p>12 EXHIBITS</p> <p>13</p> <p>14 Exhibit</p> <p>15 Name Description Page No.</p> <p>16 Defendant's Notice of Oral 10</p> <p>17 Exhibit D1 Deposition of Anne</p> <p>18 McTiernan, M.D., Ph.D.,</p> <p>19 and Duces Tecum</p> <p>20 Defendant's Collection of McTiernan 24</p> <p>21 Exhibit D2 Invoices</p> <p>22</p> <p>23 Defendant's *Placeholder for 26</p> <p>24 Exhibit D3 McTiernan invoices</p> <p>25 related to the Giese</p> <p>state court case</p> <p>22 Defendant's Curriculum Vitae of 44</p> <p>23 Exhibit D4 Anne McTiernan, M.D.,</p> <p>24 Ph.D., dated March 28,</p> <p>25 2024</p>	<p style="text-align: right;">Page 5</p> <p>1 INDEX (Continued)</p> <p>2</p> <p>3 EXHIBITS (Continued)</p> <p>4 Exhibit</p> <p>5 Name Description Page No.</p> <p>6 Defendant's Phung (2022) 112</p> <p>7 Exhibit D10 Supplemental Data,</p> <p>8 Supplementary Table 1,</p> <p>9 Characteristics of</p> <p>10 participants in the</p> <p>11 analysis by</p> <p>12 endometriosis status</p> <p>13</p> <p>14 Defendant's *Placeholder for Phung 113</p> <p>15 Exhibit D11 2022 article and</p> <p>16 supplemental table with</p> <p>17 handwritten notes of</p> <p>18 Anne McTiernan</p> <p>19</p> <p>20 Defendant's Article entitled, 138</p> <p>21 Exhibit D12 "Systematic review of</p> <p>22 the association between</p> <p>23 talc and female</p> <p>24 reproductive tract</p> <p>25 cancers," by Heather N.</p> <p>Lynch, et al.</p> <p>16 Defendant's Article entitled, "A 145</p> <p>17 Exhibit D13 critical review of talc</p> <p>18 and ovarian cancer," by</p> <p>19 Julie E.</p> <p>20 Goodman, et al.</p> <p>21</p> <p>22 Defendant's American Cancer 155</p> <p>23 Exhibit D14 Society, Cancer Facts &</p> <p>24 Figures 2024</p> <p>25</p> <p>26 Defendant's Press Release entitled, 162</p> <p>27 Exhibit D15 Biden-Harris</p> <p>28 Administration</p> <p>29 finalizes ban on</p> <p>30 ongoing uses of</p> <p>31 asbestos to protect</p> <p>32 people from cancer,"</p> <p>33 dated March 18, 2024</p>

<div>Page 6</div> <div><div>1INDEX (Continued)</div><div>2</div><div>3EXHIBITS (Continued)</div><div>4Exhibit</div><div>5</div><div>6</div><div>7</div><div>8</div><div>9</div><div>10</div><div>11</div><div>12</div><div>13</div><div>14</div><div>15</div><div>16</div><div>17</div><div>18</div><div>19</div><div>20</div><div>21</div><div>22</div><div>23</div><div>24</div><div>25</div></div> <table><thead><tr><th>Name</th><th>Description</th><th>Page No.</th></tr></thead><tbody><tr><td>Defendant's EPA Pre-Publication</td><td>162</td><td></td></tr><tr><td>Exhibit D16</td><td>Notice, entitled, "Asbestos Part I; Chrysotile Asbestos; Regulation of Certain Conditions of Use under the Toxic Substances Control Act (TSCA)," dated March 18, 2024</td><td></td></tr><tr><td>Defendant's Sisters' Study results</td><td>170</td><td></td></tr><tr><td>Exhibit D17</td><td>on vaginal/genital talc and ovarian cancer risk in 3 publications</td><td></td></tr><tr><td>Defendant's Article entitled, "Use</td><td>176</td><td></td></tr><tr><td>Exhibit D18</td><td>of personal care product mixtures and incident hormone-sensitive cancers in the Sister Study: A U.S.-wide prospective cohort," by Che-Jung Chang, et al.</td><td></td></tr><tr><td colspan="3">(*Placeholder for marked exhibit)</td></tr><tr><td colspan="3">(Exhibits attached to transcript)</td></tr><tr><td colspan="3">(Exhibits D3 and D11 not attached)</td></tr></tbody></table>	Name	Description	Page No.	Defendant's EPA Pre-Publication	162		Exhibit D16	Notice, entitled, "Asbestos Part I; Chrysotile Asbestos; Regulation of Certain Conditions of Use under the Toxic Substances Control Act (TSCA)," dated March 18, 2024		Defendant's Sisters' Study results	170		Exhibit D17	on vaginal/genital talc and ovarian cancer risk in 3 publications		Defendant's Article entitled, "Use	176		Exhibit D18	of personal care product mixtures and incident hormone-sensitive cancers in the Sister Study: A U.S.-wide prospective cohort," by Che-Jung Chang, et al.		(*Placeholder for marked exhibit)			(Exhibits attached to transcript)			(Exhibits D3 and D11 not attached)			<div>Page 8</div> <div><div>1ANNE MCTIERNAN, M. D., P.H. D.,</div><div>2having first been duly sworn, was examined and</div><div>3testified as follows:</div><div>4MS. PARFITT: And, Ms. Mullaley,</div><div>5let me make one statement before.</div><div>6We have provided you with a Dropbox</div><div>7of materials that Dr. McTiernan has</div><div>8considered in addition to, obviously, her</div><div>9report, which you have, and prior</div><div>10deposition. But there were three</div><div>11documents that were sent, I believe, this</div><div>12morning based upon Dr. McTiernan's review</div><div>13of, I guess, late last night. And I'll</div><div>14put them on the record so you have them.</div><div>15There's an article by Dr. O'Brien</div><div>16on douching, a 2022. And then there's an</div><div>17article by Dr. -- excuse me, yes, Dr. --</div><div>18I'm going to spell it -- it's</div><div>19O-G-U-N-S-I-N-A; and it's a '23 article.</div><div>20And then I believe -- and she can</div><div>21speak to it -- some -- a calculation that</div><div>22apparently she worked on last evening. So</div><div>23you have those.</div><div>24And, Kate, just for transparency,</div><div>25everything else would have been provided</div></div>
Name	Description	Page No.																													
Defendant's EPA Pre-Publication	162																														
Exhibit D16	Notice, entitled, "Asbestos Part I; Chrysotile Asbestos; Regulation of Certain Conditions of Use under the Toxic Substances Control Act (TSCA)," dated March 18, 2024																														
Defendant's Sisters' Study results	170																														
Exhibit D17	on vaginal/genital talc and ovarian cancer risk in 3 publications																														
Defendant's Article entitled, "Use	176																														
Exhibit D18	of personal care product mixtures and incident hormone-sensitive cancers in the Sister Study: A U.S.-wide prospective cohort," by Che-Jung Chang, et al.																														
(*Placeholder for marked exhibit)																															
(Exhibits attached to transcript)																															
(Exhibits D3 and D11 not attached)																															
<div>Page 7</div> <div><div>1LITIGATION SUPPORT</div><div>2</div><div>3REQUESTS</div><div>4Request</div><div>5</div><div>6</div><div>7</div><div>8</div><div>9</div><div>10</div><div>11</div><div>12</div><div>13</div><div>14</div><div>15</div><div>16</div><div>17</div><div>18</div><div>19</div><div>20</div><div>21</div><div>22</div><div>23</div><div>24</div><div>25</div></div> <table><thead><tr><th>Request Number/By</th><th>Page No.</th></tr></thead><tbody><tr><td>1/MS. MULLALEY</td><td>26</td></tr></tbody></table>	Request Number/By	Page No.	1/MS. MULLALEY	26	<div>Page 9</div> <div><div>1three days ago. But as you can</div><div>2appreciate, and I'm sure your experts will</div><div>3be the same, they continue to read and</div><div>4keep reading.</div><div>5So I just wanted to let you know;</div><div>6and hopefully, we can have that process</div><div>7going forward that if you should find</div><div>8anything with your experts right before</div><div>9deposition, you let us know as well.</div><div>10MS. MULLALEY: Yes.</div><div>11MS. PARFITT: Thank you.</div><div>12MS. MULLALEY: I don't think I've</div><div>13received those documents, but I'll just</div><div>14reach out to our people.</div><div>15MS. PARFITT: It was in the</div><div>16Dropbox. They added to the original</div><div>17Dropbox that you received.</div><div>18MS. MULLALEY: Okay.</div><div>19MS. PARFITT: Yeah. There's a</div><div>20link.</div><div>21MS. MULLALEY: Got it. Okay. I'll</div><div>22take a look at the break.</div><div>23MS. PARFITT: Thank you.</div><div>24</div><div>25</div></div>																										
Request Number/By	Page No.																														
1/MS. MULLALEY	26																														

<p style="text-align: right;">Page 18</p> <p>1 correct?</p> <p>2 A. That's correct if it's included</p> <p>3 with ovarian cancer cases in individual</p> <p>4 studies.</p> <p>5 Q. So have you done and conducted a</p> <p>6 Bradford Hill analysis to specifically whether</p> <p>7 there's an association between just fallopian</p> <p>8 tube cancer and talcum powder use?</p> <p>9 MS. PARFITT: Objection. Form.</p> <p>10 THE WITNESS: My Bradford Hill</p> <p>11 analysis was on talcum powder use; and</p> <p>12 ovarian cancer and ovarian cancer can</p> <p>13 include fallopian tube cancer.</p> <p>14 BY MS. MULLALEY:</p> <p>15 Q. And sort of in that vein, are you</p> <p>16 offering an opinion that all types of ovarian</p> <p>17 cancer, regardless of whether or not they are</p> <p>18 epithelial ovarian cancer, are associated with</p> <p>19 the genital use of talcum powder?</p> <p>20 MS. PARFITT: Objection.</p> <p>21 You may answer.</p> <p>22 THE WITNESS: My opinion is that</p> <p>23 talcum powder use can cause all types of</p> <p>24 epithelial ovarian cancer.</p> <p>25</p>	<p style="text-align: right;">Page 20</p> <p>1 MS. PARFITT: Objection. Asked and</p> <p>2 answered.</p> <p>3 THE WITNESS: That's correct.</p> <p>4 BY MS. MULLALEY:</p> <p>5 Q. And is it fair to say that you have</p> <p>6 not the formed an opinion as to whether or not</p> <p>7 ovarian carcinosarcoma is caused by -- or is</p> <p>8 associated with the use of talcum powder?</p> <p>9 MS. PARFITT: Objection. Asked and</p> <p>10 answered.</p> <p>11 And, Kate, the purpose of those</p> <p>12 objections is that these questions were</p> <p>13 inquiries that were made at the prior two</p> <p>14 depositions.</p> <p>15 MS. MULLALEY: And just to add that</p> <p>16 I did my very best to go back and look</p> <p>17 through all of Dr. McTiernan's prior</p> <p>18 testimony, and I did not see questions</p> <p>19 about specifically germ cell, stromal,</p> <p>20 small cell; and then I specifically just</p> <p>21 asked about the other gynecological</p> <p>22 cancers just based on what</p> <p>23 Ms. McTiernan -- or Dr. McTiernan said</p> <p>24 about reliance on the Chang.</p> <p>25 MS. PARFITT: Okay. And that's why</p>
<p style="text-align: right;">Page 19</p> <p>1 BY MS. MULLALEY:</p> <p>2 Q. So have you formed the -- so is it</p> <p>3 fair to say that you've not formed the opinion</p> <p>4 or it is not your opinion -- sorry. Strike</p> <p>5 that. I'll start over.</p> <p>6 Is it fair to say that you have not</p> <p>7 formed the opinion that the genital use of</p> <p>8 talcum powder products can cause germ cell</p> <p>9 ovarian cancer?</p> <p>10 MS. PARFITT: Objection. Asked and</p> <p>11 answered.</p> <p>12 THE WITNESS: That's correct.</p> <p>13 BY MS. MULLALEY:</p> <p>14 Q. And are you -- is it fair to say</p> <p>15 that you have not formed the opinion as to</p> <p>16 whether stromal cell ovarian cancer is</p> <p>17 associated with the use of talcum powder?</p> <p>18 MS. PARFITT: Objection. Asked and</p> <p>19 answered.</p> <p>20 THE WITNESS: That's correct.</p> <p>21 BY MS. MULLALEY:</p> <p>22 Q. And it's fair to say that you have</p> <p>23 not formed the opinion that small cell</p> <p>24 carcinomas of the ovary are associated with the</p> <p>25 use of talcum powder?</p>	<p style="text-align: right;">Page 21</p> <p>1 I was giving a little bit of a runway.</p> <p>2 Some of these are pretextual, and I hope</p> <p>3 that that we can work that way; but they</p> <p>4 were asked in different forms, but same</p> <p>5 answer. But thank you.</p> <p>6 BY MS. MULLALEY:</p> <p>7 Q. So, Dr. McTiernan, just going back</p> <p>8 to the studies, the three studies, that you</p> <p>9 specifically reviewed over the weekend.</p> <p>10 Is it your testimony that the first</p> <p>11 time that you reviewed the O'Brien 2022 study</p> <p>12 was this weekend, or were you just re-reviewing</p> <p>13 it?</p> <p>14 A. So these studies you're talking</p> <p>15 about are the fibroid and -- well, why don't</p> <p>16 you -- why don't you mention which of the three</p> <p>17 studies you're talking about because there are</p> <p>18 a lot of O'Brien studies in my reliance.</p> <p>19 Q. It was the -- I believe you</p> <p>20 mentioned that you had reviewed over the</p> <p>21 weekend O'Brien 2022, Ogunsina 2023; and then I</p> <p>22 think you had also -- was it a study or just</p> <p>23 you had prepared some calculations?</p> <p>24 A. Yes. I prepared some calculations</p> <p>25 from the Chang study and Gonzalez and also the</p>

<p style="text-align: right;">Page 22</p> <p>1 Sister Study data that was in the O'Brien 2 pooled analysis. 3 Q. And so was that -- going back to my 4 question, was this O'Brien 2022 study that you 5 reviewed over the weekend, was that the first 6 time that you reviewed that study? 7 A. And you're talking O'Brien 2022 is 8 the cervical cancer study? 9 Let's see. I don't have the dates 10 memorized. 11 MS. PARFITT: It's the Nature study 12 if that helps direct. And I appreciate 13 your letting me know that. 14 THE WITNESS: Yes. So this weekend 15 would have been the first time I looked at 16 that, yes. 17 BY MS. MULLALEY: 18 Q. Was the Ogunsina the first study -- 19 the 2023 study that you reviewed over the 20 weekend, was that the first time that you 21 reviewed that study? 22 A. I may have seen it before, but I 23 didn't read it in depth. And by saying I saw 24 it before, I may have seen it on a previous 25 reference or a previous search because I</p>	<p style="text-align: right;">Page 24</p> <p>1 you with the Ogunsina 2023 article? 2 MS. PARFITT: Objection. Form. 3 THE WITNESS: I can't recall if I 4 downloaded this or if it was sent. It may 5 have been sent because we -- we -- they 6 knew that I had done this search. But I 7 just -- I just can't remember if I had -- 8 which one I'm looking at, if I'm looking 9 at one that I sent or one that I 10 downloaded. 11 BY MS. MULLALEY: 12 Q. So I'd need to ask you some 13 questions. One of the documents -- some of the 14 documents that you produced to us last week 15 include a number of your invoices, and I'd like 16 to ask you some questions about those invoices. 17 I'd like to go ahead and mark the 18 collection of invoices that you produced on 19 March 28th, 2024, as Exhibit 2. And that 20 should be Tab 2 in your binder, Dr. McTiernan. 21 (Whereupon, Defendant's Exhibit D2, 22 Collection of McTiernan Invoices, was 23 marked for identification.) 24 THE WITNESS: Okay. 25</p>
<p style="text-align: right;">Page 23</p> <p>1 recalled the fibroids is something that had 2 been looked at. But because it wasn't -- I 3 didn't look in depth at it, so this is the 4 first time I really read it. 5 Q. Why did you review the Ogunsina 6 2023 study? And. 7 Apologies if I'm messing up the 8 pronunciation. 9 A. Because I was interested in what 10 other things these authors, the Sister Study 11 authors had looked at and how they had 12 approached it for different outcomes. 13 And, you know, these -- these are 14 out comes that are in the same women, the same 15 study that the Sister Study ovarian cancer 16 analysis was done in. 17 Q. Does the Ogunsina 2023 article 18 impact your opinions in this case in any way? 19 MS. PARFITT: Objection. Form. 20 THE WITNESS: It doesn't include 21 data on ovarian cancer, and it doesn't 22 affect my opinion on the association 23 between ovarian cancer and use of talc. 24 BY MS. MULLALEY: 25 Q. Did the plaintiff's lawyers provide</p>	<p style="text-align: right;">Page 25</p> <p>1 BY MS. MULLALEY: 2 Q. And so first off, are these all the 3 invoices that you have submitted to the 4 plaintiff's lawyers for your work in the talc 5 litigation from August 2021 to today? 6 A. They should be. I'm trying to see 7 these dates. It looks like it's complete. I 8 don't have my own invoices in front of me, so I 9 can't be absolutely sure; but I did talk about 10 it -- a little bit about it before. So if they 11 sent everything that we talked about, then it 12 would be complete. 13 Q. I noticed that a these invoices do 14 not include your work on the Giese trial. 15 In addition to the Giese trial, do 16 you have any invoices from any other talc cases 17 that were not produced last week? 18 MS. PARFITT: And you're referring 19 to the Giese -- the state court trial? 20 MS. MULLALEY: Yes. 21 MS. PARFITT: Okay. I believe 22 those were, frankly, provided to counsel 23 during the course of that particular 24 litigation. We did not -- Dr. McTiernan 25 was not an expert for -- for our firm in</p>

7 (Pages 22 - 25)

Page 170

1 deposition, have you conducted a Bradford Hill
2 analysis to analyze the association between
3 clear cell carcinoma and perineal talc use?
4 MS. PARFITT: Objection. Form.
5 THE WITNESS: No.
6 BY MS. MULLALEY:
7 Q. I want to now turn to the table
8 that you produced this morning, I think, at
9 8 a.m. Eastern Time. It is a table of three
10 studies called, "Sisters' Study results on
11 vaginal/genital talc and ovarian cancer risk in
12 3 publications."
13 MS. MULLALEY: And I'll go ahead
14 and mark that as Exhibit 17.
15 (Whereupon, Defendant's
16 Exhibit D17, Sisters' Study results on
17 vaginal/genital talc and ovarian cancer
18 risk in 3 publications, was marked for
19 identification.)
20 BY MS. MULLALEY:
21 Q. Do you have a copy of that in front
22 of you?
23 A. I do, yes.
24 Q. When did you prepare this table?
25 A. So this would have been yesterday,

Page 171

1 the day before. No. I started it the day
2 before, fixed it up yesterday, and sent it to
3 the lawyers last night.
4 Q. Did the lawyers ask you to prepare
5 this table?
6 A. No.
7 Q. And why did you prepare this table?
8 A. Because this is -- these are
9 results from one study, and I've seen from
10 years of doing epidemiology and also from years
11 of reviewing intel, that cohort studies often
12 will redo analyses for a given exposure when
13 they have more cases are accrued to this study.
14 And so Sister Study, their first
15 study was published in 2016. They only had 154
16 cases then. But I notes had when I looked at
17 Chang, that that study, that they had 277
18 cases. So almost twice as many cases.
19 And so I knew that also the O'Brien
20 pooled analysis had data from Sisters. And so
21 I wanted to see what had happened over time in
22 these three analyses of the same study, same
23 data that was collected at baseline to see
24 what -- how the association between perineal
25 talcum powder use and ovarian cancer risk

Page 172

1 changed if it did.
2 I use the word "genital" up top
3 because one of the authors calls it genital. I
4 can't -- I think it's Chang calls it -- sorry,
5 Chang calls it vaginal, but the other ones seem
6 to call it genital.
7 And so what I did was, then, look
8 at the number of years followed, the median
9 number of years that they reported for each of
10 those publications; the number of cases -- N
11 means number -- the number of cases that were
12 in each of those publications, cases of ovarian
13 cancer; what they defined as talc use, and the
14 first study and Gonzalez, it was only ever
15 versus never use.
16 The O'Brien pooled looked at --
17 sorry. Gonzalez was ever in the 12 months
18 before entering the study. O'Brien looked at
19 ever either in the 12 months before study entry
20 or at age 10 to 13. And then Chang created a
21 variable, and that variable was for each one
22 unit increase in frequency of use what's the
23 risk of ovarian cancer.
24 So the relative risk that Gonzalez
25 was reported 0.73, so that's less than 1. It's

Page 173

1 not showing an increased risk. In -- at -- in
2 O'Brien those pooled data showed that ever
3 versus never increased risk of 1.02, so it's no
4 longer a negative, no longer below 1.
5 And then Chang looked -- computed
6 the variable of per-unit change and found for
7 each one unit increase, the relative risk was
8 1.06.
9 Now, what they interpret in Chang,
10 they help us understand what that one unit
11 increase means. And they say -- they use the
12 example for one of their breast cancer results,
13 and it says, "Although the observed effects of
14 a one-frequency-level increase were modest in
15 magnitude, the impact would be more
16 substantially -- substantial when comparing the
17 most frequent users with the never users. For
18 example, in 8 percent higher hazard of the
19 postmenopausal breast cancer for
20 one-frequency-level increase in the beauty
21 mixture could translate to approximately a
22 36-percent higher hazard for the most frequent
23 users compared with the never users."
24 So on the -- the right-hand column,
25 I look at relative risk for frequent use in

<p style="text-align: right;">Page 174</p> <p>1 those three publications. Gonzalez did not 2 present that. The O'Brien pooled analysis 3 showed a relative risk of 1.25 with a 4 confidence interval of 0.76 to 2. And then 5 Chang gave us the one-unit increase. 6 And so in order to get to the fifth 7 level, which is five or more times a week -- 8 that's the most frequent -- you would multiply 9 1.6 times 1.6 times 1.6 -- sorry, 1. -- sorry. 10 Start again. 11 Multiply 1.06 times 1.06 times 1.06 12 times 1.06 for a number -- a hazard ratio 13 relative risk of 1.26 or a 26-percent increased 14 risk. 15 So this tells me two things: One, 16 this cohort study is showing similar results to 17 some of the case controlled studies and the 18 pooled meta-analyses of elevated relative risk 19 with use of ovar- -- with use of perineal talc. 20 And it also shows that change in 21 time with more follow-up, more numbers of 22 cases, you get a change in the relative risk 23 that is seen. So the first Sister Study was 24 very early look, and it was premature, it turns 25 out, because when you follow people longer and</p>	<p style="text-align: right;">Page 176</p> <p>1 THE WITNESS: My table used the 2 same method that they showed of how to 3 calculate the odds ratio and didn't 4 require in knowing the numbers of women in 5 each particular category. 6 BY MS. MULLALEY: 7 Q. So I'd like to mark as 8 Exhibit 17 -- sorry 18, the Chang 2024 study; 9 and it is Tab 17 in your -- in your binder, the 10 second volume binder. 11 (Whereupon, Defendant's 12 Exhibit D18, Article entitled, "Use of 13 personal care product mixtures and 14 incident hormone-sensitive cancers in the 15 Sister Study: A U.S.-wide prospective 16 cohort," by Che-Jung Chang, et al., was 17 marked for identification.) 18 BY MS. MULLALEY: 19 Q. Dr. McTiernan, if you turn to 20 page 3 of Chang 2024 under Section 2.5, 21 Statistical Analysis -- 22 A. I'm sorry. Which -- which page are 23 you talking about of Chang? 24 Q. Page -- page 3 of Chang. 25 A. Okay.</p>
<p style="text-align: right;">Page 175</p> <p>1 you look at frequent use, you see an elevated 2 risk. 3 Q. So Dr. McTiernan, you know the 4 authors of Chang 2024 never provided an HR for 5 women who used vaginal talc five times a week, 6 right? 7 A. They provide a relative risk for 8 those who used one-unit change. So they 9 provided a relative risk of 1.06 for each 10 one-unit change, and then they showed us what I 11 read off. They specified at the very last 12 paragraph of the paper of how to interpret what 13 that level means when you look at the highest 14 level. 15 Q. Right. But do you know how many 16 women in Chang 2024 reported using vaginal talc 17 five times per week? 18 MS. PARFITT: Objection. Form. 19 THE WITNESS: I would have to see 20 if they provided it. 21 BY MS. MULLALEY: 22 Q. But you don't know off the top of 23 your head having done this -- preparing this 24 table over the weekend? 25 MS. PARFITT: Objection. Form.</p>	<p style="text-align: right;">Page 177</p> <p>1 Q. Under Section 2.5, Statistical 2 Analysis, the third paragraph, Chang 2024 3 states, quote, "The five level frequency 4 categories of PCP use were treated as 5 continuous variables in all of our analyses 6 assuming an approximate linear relationship and 7 uniform change in the hazard for each increase 8 in the frequency measure." 9 Do you see that? 10 A. Yes. 11 Q. So here they're saying that -- that 12 they're assuming approximate linear 13 relationship, right? 14 A. Yes. 15 Q. So essentially, this HR that you 16 hypothetically modeled of 1.26 is not based on 17 actual data from the users five times a week, 18 right? 19 A. That's not what that says, to my 20 understanding. My understanding, they use all 21 of the data. They put it all in, and they 22 model it to come up with the relative risk that 23 they see overall for each one-unit change. And 24 this is similar to what's done in epidemiologic 25 studies.</p>

<p style="text-align: right;">Page 182</p> <p>1 It's not hypothetical. It's real 2 numbers. 3 BY MS. MULLALEY: 4 Q. But you don't have a confidence 5 interval, right? 6 MS. PARFITT: Objection. Form. 7 THE WITNESS: I didn't have the -- 8 I didn't feel that I had the correct 9 numbers for doing confidence intervals. 10 They didn't provide that in the 11 description at the end of the article. 12 They showed how to calculate the 13 relative risk or hazard ratio for the 14 highest versus lowest level of exposure. 15 BY MS. MULLALEY: 16 Q. And because you don't have a 17 confidence interval to go with this 1.26 18 calculation, there's no way for us to know if 19 it's significant -- 20 MS. PARFITT: Objection. 21 BY MS. MULLALEY: 22 Q. -- right? 23 MS. PARFITT: Objection. Form. 24 Misstates her testimony. 25 THE WITNESS: We just know what it</p>	<p style="text-align: right;">Page 184</p> <p>1 Would you agree, Dr. McTiernan, 2 that all three studies on this Exhibit 17 chart 3 that you prepared over the weekend, Gonzalez 4 2016, O'Brien 2020, and Chang 2024, there is 5 not a single statistically significant 6 association reported between vaginal talc use 7 and ovarian cancer? 8 MS. PARFITT: Objection. Misstates 9 the evidence and her testimony. 10 THE WITNESS: I have not looked, 11 again, through all of the data from 12 O'Brien beyond what I inserted into this 13 table; and so I can't answer for that 14 study. 15 I can say from Chang that I 16 couldn't calculate on hazard ratio -- I 17 couldn't calculate the confidence 18 intervals because I didn't feel like I had 19 the right information to do that; so I 20 don't know what that would be. 21 They presented a relative risk of 22 1.06 with a confidence interval of .9 to 23 1.24. So if they're using -- so that 24 tells us that it's a 95-percent chance 25 that the relative risk would fall within</p>
<p style="text-align: right;">Page 183</p> <p>1 is and what the authors say could be -- 2 let me see; what are the words that they 3 use -- could translate to a higher hazard 4 of most frequent versus never users. 5 BY MS. MULLALEY: 6 Q. Can you point me to in the Chang 7 2024 article where Chang provides the number of 8 women who reported using vaginal talc five 9 times per week? 10 A. Okay. I'll have to read this and 11 look at the tables. 12 Q. So we don't burn time, do you want 13 to take a break and so you can review the Chang 14 2024 article again? 15 A. No. I can see -- I can see and 16 from my memory also, they did -- they did not 17 include the numbers in each category. They 18 were looking at multiple exposures. 19 They did state that -- however, 20 that both douche and genital talc use were the 21 most important contributors to a mixture of 22 hygiene effects, which was consistent with 23 previous findings. 24 Q. Also, on this table that you 25 have -- strike that.</p>	<p style="text-align: right;">Page 185</p> <p>1 that category. 2 If they're using point -- so if 3 they're using -- if they're assuming a 4 confidence interval that includes one 5 means not statistically significant, then 6 that would be the case for this. 7 One of the things that is new here 8 is that this model does adjust for other 9 personal care products, so that's a unique 10 analysis from the Sister Study. 11 BY MS. MULLALEY: 12 Q. And, Dr. McTiernan, I just want to 13 go back to one other question that I was asking 14 you earlier about performing a Bradford Hill 15 analysis about the -- specifically about the 16 subtypes of epithelial ovarian cancer. 17 Is it your opinion that borderline 18 ovarian cancer is associated with the use of 19 perineal talcum powder? 20 MS. PARFITT: Objection. Asked and 21 answered I think just a few minutes ago. 22 Counsel, I'm not try- -- 23 MS. MULLALEY: And it's the 24 distinction about whether she performed 25 the Bradford Hill analysis versus her</p>